to the liver and promote patient-derived xenograft tumour growth

Slides:

Advertisements

Similar presentations

Figure 4 PET imaging in experimental pancreatic cancer

Advertisements

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Low-grade inflammation in FGID

Figure 1 Key elements of cancer-related inflammation

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Gut microorganisms at the intersection of several diseases

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.

Figure 1 Host range of hepatitis E virus

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Differences between MC and AC

Figure 1 Exosomes with siRNAs targeting

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Urol. doi: /nrurol

Figure 1 Environmental factors contributing to IBD pathogenesis

different types of liver cells

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 13C-octanoic acid gastric emptying breath test

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 3 Lipid droplet formation and expansion

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Animal models of liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 5 Systems biological model of IBS

Figure 4 Local species pools that contribute to the

Figure 1 Cancer stem cell plasticity and stem cell homeostasis in the gut Figure 1 | Cancer stem cell plasticity and stem cell homeostasis in the gut.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Figure 2 Classifications and appearance of CCAs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 The spread of colorectal cancer metastases

Presentation transcript:

to the liver and promote patient-derived xenograft tumour growth Figure 1 Fusobacterium translocate with primary colorectal cancer cells to the liver and promote patient-derived xenograft tumour growth Figure 1 | Fusobacterium translocate with primary colorectal cancer cells to the liver and promote patient-derived xenograft tumour growth. Bullman et al.10 showed that the same Fusobacterium species were present in paired primary and metastatic tumour samples from patients with colorectal cancer (CRC) and that the Fusobacterium-killing antibiotic metronidazole, but not erythromycin, inhibited patient-derived xenograft tumour growth. Yang, Y. & Jobin, C. (2018) Hand‑in‑hand — colorectal cancer metastasizes with microorganisms Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.186